Литература
1. Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. Москва: ГЭОТАР-Медиа; 2008. С. 290 — 331
2. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016 Oct 22; 388(10055): 2023 — 2038. doi: 10.1016/S0140-6736(16)30173-8
3. Фоломеева О.М., Галушко Е.А., Эрдес Ш.Ф. Распространенность ревматических заболеваний в популяциях взрослого населения России и США. Научно-практическая ревматология. 2008; 46(4): 4 — 13. DOI:10.14412/1995-4484-2008-529
4. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Amer 2009; 35: 745 — 57, vii — viii. doi: 10.1016/j.rdc.2009.10.001.
5. Machado P, Castrejon I, Katchamart W, Koevoets R, Kuriya B, Schoels M, , Thevissen K, Vercoutere W, Villeneuve E, Aletaha D, Carmona L, , van der Heijde D, Bijlsma JW, Bykerk V, , Catrina AI, Durez P, Edwards CJ, Mjaavatten MD, Leeb BF, Losada B, , Martinez-Osuna P, Montecucco C, , , Sheane B, Xavier RM, Zochling J, Bombardier C. Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2011; 70(1): 15 — 24. doi: 10.1136/ard.2010.130625MADAMA
6. Hua C, Daien CI, Combe B, Landewe R. Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis. RMD Open 2017 Jan 5; 3(1): e000406. doi: 10.1136/rmdopen-2016-000406
7. Jilani AA, Mackworth-Young CG. The role of citrullinated protein antibodies in predicting erosive disease in rheumatoid arthritis: a systematic literature review and meta-analysis. Int J Rheumatol 2015; 2015: 728610. doi: 10.1155/2015/728610
8. Taylor P, Gartemann J, Hsieh J et al. A systematic review ofserum biomarkers anti-cyclic citrullinated peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Dis 2011; 2011: 815038.
9. Schoels M, Bombardier C, Aletaha D. Diagnostic and prognostic value of antibodies and soluble biomarkers in undifferentiated peripheral inflammatory arthritis: a systematic review. J Rheumatol Suppl 2011; 87: 20 — 5. doi: 10.3899/jrheum.101070
10. Nishimura K, Sugiyama D, Kogata Y et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146: 797 — 808. doi:10.7326/0003-4819-146-11-200706050-00008
11. Aletaha D, . Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open. 2016 May 17; 2(1): e000009. doi: 10.1136/rmdopen-2014-000
12. Takase-Minegishi K, Horita N, Kobayashi K, Yoshimi R, Kirino Y, Ohno S, Kaneko T, Nakajima H, Wakefield RJ, Emery P. Diagnostic test accuracy of ultrasound for synovitis in rheumatoid arthritis: systematic review and meta-analysis. Rheumtology (Oxford) 2017 Mar 3.doi: 10.1093/rheumatology/kex036
13. Szkudlarek M, Terslev L, Wakefield RJ, Backhaus M, Balint PV etal. Summary Findings of a Systematic Literature Review of the Ultrasound Assessment of Bone Erosions in Rheumatoid Arthritis. J Rheumatol 2016; 43(1): 12 — 21. doi: 10.3899/jrheum.141416
14. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631 — 7
15. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with systemic and biological disease-modifying anti-rheumatic drugs: 2013. Ann Rheum Dis. 2014; 73: 492 — 5009.
16. Насонов ЕЛ, Мазуров ВИ, Каратеев ДЕ и др. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России» — 2014 (часть 1). Научно-практическая ревматология. 2014; 52: 477 — 494.
17. Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Рекомендации EULAR по лечению ревматоидного артрита — 2013: общая характеристика и дискуссионные проблемы. Научно-практическая ревматология. 2013; 51: 609 — 622.
18. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheum 2016; 68: 1 — 26. Doi: 10.1002/art.39489.
19. Smolen JS, van der Heijde D, Machold KP, et al. Proposal for anew nomenclature of disease-modifying anti-rheumatic drugs. Ann Rheum Dis. 2014; 73: 3 — 5
20. Daien CI, Hua C, Combe B, Landewe R. Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis. RMD Open 2017 Jan 5; 3(1): e000404. doi: 10.1136/rmdopen-2016-000404
21. Widdifield J, Bernatsky S, Paterson JM, et al. Quality care inseniors with new-onset rheumatoid arthritis: a Canadian perspective. Arthritis Care Res (Hoboken) 2011; 63: 53 — 7. doi: 10.1002/acr.20304
22. Memel DS, Somerset M. General practitioner and specialist care: the perceptions of people with rheumatoid arthritis. Prim Health Care Res Dev 2003; 4: 29 — 37. doi: 10.1191/1463423603pc120oa
23. Robinson PC, Taylor WJ. Time to treatment in rheumatoid arthritis: factors associated with time to treatment initiation and urgent triage assessment of general practitioner referrals. J Clin Rheumatol 2010; 16: 267 — 73. doi: 10.1097/RHU.0b013e3181eeb499
24. Kyburz D, Gabay C, Michel BA, et al. The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study. Rheumatology (Oxford) 2011; 50: 1106-10. doi: 10.1093/rheumatology/keq424
25. Feldman DE, Bernatsky S, Houde M, et al. Early consultation with a rheumatologist for RA: does it reduce subsequent use of orthopaedic surgery? Rheumatology (Oxford) 2013; 52: 452 — 9. doi: 10.1093/rheumatology/kes231
26. Насонов Е.Л., Яхно Н.Н., Каратеев А.Е., Алексеева ЛИ., Баринов АН., Барулин АЕ, Давыдов О.С., Данилов А.Б., Журавлева М.В., Заводовский Б.В., Копенкин С.С., Кукушкин М.Л., Парфенов В.А., Страхов М.А., Тюрин В.П., Чичасова Н.В., Чорбинская С.А. Общие принципы лечения скелетно-мышечной боли: междисциплинарный консенсус. Научно-практическая + ревматология. 2016; 54: 247 — 265. DOI: 10.14412/1995-4484-2016247-265
27. Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008; 12: 1 — 278.
28. van Walsem A, Pandhi S, Nixon RM, Guyot P, Karabis A, Moore RA. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Res Ther. 2015 Mar 19; 17: 66. doi: 10.1186/s13075-015-0554-0
29. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ. 2002; 325: 619. doi: 10.1136/bmj.325.7365.619
30. Salvo F, Fourrier-Reglat A, Bazin F, Robinson P, Riera-Guardia N, Haag M, et al. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther. 2011; 89: 855 — 66. doi: 10.1038/clpt.2011.45
31. Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382: 769 — 79. doi: 10.1016/S01406736(13) 60900 — 9.
32. Colebatch AN, Marks JL, Edwards CJ. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev. 2011 Nov 9; (11): CD008872. doi: 10.1002/14651858.CD008872
33. Simon LS. Non-steroidal anti-inflammatory drugs and their benefits and harms: the challenge of interpreting meta-analyses and observational data sets when balanced data are not analyzed and reported. Arthritis Res Ther. 2015 21; 17: 130. doi: 10.1186/s13075015-0650-1.
34. Gaujoux-Viala C, Mitrovic S, Barnetche T et al. Efficacy of glucocorticoids for early rheumatoid arthritis (RA): a meta-analysis of randomised controlled trials. Ann Rheum Dis 2014; 73: 218.
35. Mitrovic S, Fardet L, Vatier C et al. THU0142 Safety of glucocorticoids for early rheumatoid arthritis: a meta-analysis of randomised controlled trials. Ann Rheum Dis 2014; 73: 228 doi: 10.1136/annrheumdis-2014-eular.5481
36. Lopez-Olivo MA, Siddhanamatha HR, Shea B, Tugwell P, Wells GA, Suarez-Almazor ME. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2014; 6: CD000957
37. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database Syst Rev. 2010; 4: CD008495
38. National Institute for Health and Care Excellence (UK). Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed [online], (2016).
39. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Tanjong Ghogomu E, Tugwell P. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009 Oct 7; (4): CD007848. doi: 10.1002/14651858.CD007848.pub2
40. Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014; 73: 516 — 28. doi: 10.1136/annrheumdis-2013-204577
41. Gaujoux-Viala C, Nam J, Ramiro S, et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014; 73: 510 — 5. doi: 10.1136/annrheumdis-2013-204588
42. Hazlewood GS, Barnabe C, Tomilison G, Marshall D, Devoe D, Bombardier C. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systemic review and network meta-analysis. BMJ 2016; 353: i1777. Doi: 10.1136/bmj.i1777
43. Chatzidionysiou K, Emamikia S, Nam J, Ramiro S, Smolen J, vander Heijde D, Dougados M, Bijlsma J, Burmester G, Scholte M, van Vollenhoven R, . Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017 Mar 29. pii: annrheumdis-2016-210711. doi: 10.1136/annrheumdis-2016-210711
44. Gaujoux-Viala C, Smolen JS, , et al. Current evidence for the management of rheumatoid arthritis with synthetic disease modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1004 — 9. doi: 10.1136/ard.2009.127225
45. Visser K, van der Heijde D. Optimal dosage and rout of administration of methotrexate in rheumatoid arthritis: a systemic review of the literature. Ann Rheum Dis 2009; 68: 1094 — 1099
46. Todoerti M, Maglione W, Bernero E, et al. Systematic review of 2008 — 2012 literature and update of recommendations for the use of methotrexate in rheumatic diseases, with a focus on rheumatoid arthritis. Reumatismo. 2013; 65(5): 207 — 218
47. Molina JT, Garcia FJB, Alen JC, et al. Recommendations for the use of methotrexate in rheumatoid arthritis: up and down scaling of the dose and administration routes. Rheumatol Clin 2015; 11: 3 — 8
48. Tornero Molina J, Calvo Alen J, Ballina J, , Blanco FJ. Recommendations for the use of parenteral methotrexate in rheumatic diseases. Rheumatol Clin 2017 Jan 9. pii: S1699258X(16)30162-0. doi: 10.1016/j.reuma.2016.12.001
49. Katchamart W, Bourre-Tessier J, Donka T, Drouin J, Rohekar G, Bykerk VP. Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis. J Rheumatol 2010; 37: 1422 — 1430 http://dx.doi.org/10.3899/jrheum.090978
50. Mouterde G, Baillet A, Gaujoux-Viala C, A. Cantagrel A, Wendling D, Le Loet X. Optimizing methotrexate therapy in rheumatoid arthritis: A systematic literature review. Joint Bone Spine. 2011; 78: 587 — 592
51. Насонов Е.Л. Лечение ревматоидного артрита 2012: место метотрексата. Научно-практическая ревматология 2012; 51 (приложение): 1 — 24
52. Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно-практическая ревматология 2014; 52: 8 — 26.
53. , Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016; 75: 795 — 810. doi: 10.1136/annrheumdis-2015-208840
54. Shea B, Swinden MV, Tanjong Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013; 5: CD000951
55. Hameed B, Jones H. Subcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritis. Int J Rheum Dis. 2010; 13(4): e83 — e84
56. Bianchi G, Caporali R, Todoerti M, Mattana P. Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration. Adv Ther. 2016; 33(3): 369 — 378.
57. Branco JC, Barcelos A, de , et al. Utilization of subcutaneous methotrexate in rheumatoid arthritis patients after failure or intolerance to oral methotrexate: a Multicenter Cohort Study. Adv Ther. 2016; 33(1): 46 — 57
58. Pichlmeier U, Heuer KU. Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. Clin Exp Rheumatol. 2014; 32(4): 563 — 571
59. Yadlapati S, Efthimiou P. Inadequate response or intolerability to oral methotrexate: is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics? Rheumatol Int. 2016; 36(5): 627 — 633
60. Li D, Yang Z, Kang P, Xie X. Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: a systematic review and meta-analysis. Semin Arthritis Rheum. 2016; 45(6): 656 — 662.
61. Kromann CB, Lage-Hansen PR, Koefoed M, Jemec GB. Does switching from oral to subcutaneous administration of methotrexate influence on patient reported gastro-intestinal adverse effects? J Dermatolog Treat. 2015; 26(2): 188 — 190.
62. Hazlewood GS, Thorne JC, Pope JE, et al. The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis. 2016; 75(6): 1003 — 1008.
63. Scott DG, Claydon P, Ellis C. Retrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: the MENTOR study. Scand J Rheumatol. 2014; 43(6): 470 — 476.
64. Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses >= 15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014; 73(8): 1549 — 1551
65. Braun J, , Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008; 58(1): 73 — 81
66. Gottheil S, Thorne JC, Schieir O, et al. Early use of subcutaneous MTX monotherapy vs. MTX oral or combination therapy significantly delays time to initiating biologics in early RA. Arthritis Rheumatol. 2016 68 (suppl 10)
67. Fitzpatrick R, Scott DG, Keary I. Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate. Clin Rheumatol 2013; 32: 1605 — 1612 http://dx.doi.org/10.1007/s10067-013-
68. Borman P, Demir G, Kaygisiz F, Okumus M. Subcutaneous (sc) methotrexate (MTX) is better and well-tolerable than oral MTX in rheumatoid arthritis patients, switched from oral to sc administration due to gastrointestinal side effects. Open Rheumatol J 2014; 8: 18 — 19 http://dx.doi.org/10.2174/1874312901408010018
69. Stamp LK, Barclay ML, O’Donnell JL, Zhang M, Drake J, Frampton C. Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. J Rheumatol. 2011; 38: 2540 — 2547 http://dx.doi.org/10.3899/jrheum.110481
70. Striesow F, Brandt A. Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: Results of a posmarketing surveillance study with a high-concentration formulation. Ther Adv Musculoskelet Dis 2012; :3 — 9 http://dx.doi.org/10.1177/1759720X11431004
71. Muller-Ladner U, Rockwitz K, Brandt-Jurgens J, Haux R, Kastner P, Braun J. Tolerability and patient/physician satisfaction with subcutaneously administered methotrexate provided in two formulations of different drug concentrations in patients with rheumatoid arthritis. Open Rheumatol J 2010; 4: 15 — 22 http://dx.doi.org/10.2174/1874312901004010015
72. Bakker MF, Jacobs JW, Welsing PM, et al. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in tight control treatment strategy for rheumatoid arthritis. Post hoc analisis of the CAMERA study. Ann Rheum Dis 2010; 69: 1849 — 52. doi: 10.1136/ard.2009.124065
73. Muller RB, von Kempis J, Haile SR, Schiff MH. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen cohort. Semin Arthritis Rheum 2015; 45: 28 — 34. doi: 10.1016/j.semarthrit.2015.02.0092015;
74. Palmowski Y, Buttgereit T, Dejaco C, Bijlsma JW, Matteson EL, Voshaar M, Boers M, Buttgereit F. The «official view» on glucocorticoids in rheumatoid arthritis.A systematic review of international guidelines and consensus statements. Arthritis Care Res (Hoboken). 2016 Dec 28. doi: 10.1002/acr.23185
75. Strehl C, Bijlsma JW, de Wit M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptable low level of harm to facilitate implementation of existing recommendations: view points from an EULAR task force. Ann Rheum Dis 2016; 75: 952 — 957. Doi: 10.1136/annrheumdis-2015-208916
76. Golicki D1, Newada M, Lis J, Pol K, Hermanowski T, . Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials. Pol Arch Med Wewn 2012; 122(1 — 2): 22 — 32.
77. Donahue KE1, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, Hansen RA, Morgan LC, Lohr KN. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148(2): 124 — 34
78. Singh JA, Furst D, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying anti-rheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012; 64: 625639.
79. Насонов ЕЛ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013) — место глюкокортикоидов. Научно-практическая ревматология 2015; 53: 238 — 250
80. Briot K, Cortet B, Roux C, Fardet L, Abitbol V, Bacchetta J, Buchon D, Debiais F, Guggenbuhl P, Laroche M, Legrand E, Lespessailles E, Marcelli C, Weryha G, Thomas T; Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO). 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Joint Bone Spine. 2014 Dec; 81(6): 493 — 501.
81. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, , Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One. 2012; 7(1): e30275. doi: 10.1371/journal.pone.0030275
82. Bergrath E, Gerber RA, Gruben D, Lukic T, Makin C, Wallenstein G. Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network meta-analysis. Int J Rheumatol. 2017; 2017: 8417249. doi: 10.1155/2017/8417249
83. Schoels M, Aletaha D, Smolen JS, et al. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012; 71: 1303 — 8. doi: 10.1136/annrheumdis-2011-200490
84. Nam JL, Takase-Minegishi K, Ramiro S, Chatzidionysiou K, Smolen JS, van der Heijde D et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2017 Mar 10. pii: annrheumdis-2016-210713. doi: 10.1136/annrheumdis-2016210713
85. Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D, Young A, Wailoo A. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess. 2016 Nov; 20(35)
86. Singh JA, Hossain A, Tanjong Ghogomu E, Kotb A, Christensen R, Mudano AS, Maxwell LJ, Shah NP, Tugwell P, Wells GA. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2016 May 13; (5): CD012183. doi: 10.1002/14651858.CD012183
87. Jorgensen TS, Tarp S, Furst DE, et al. Added-value of combining methotrexate with a biological agent compared to biological monotherapy in patients with rheumatoid arthritis: a systemic review and meta-analysis of randomized trials. Ann Rheum Dis 2015; 74 (Suppl 2): 239/ doi: 10.1136/annrheumdis-2015-eular.3396
88. Choy E, Aletaha D, Behrens F, Finckh A, Gomez-Reino J, Gottenberg JE, Schuch F, Rubbert-Roth A. Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Rheumatology (Oxford) 2016 Aug 21. pii: kew271.
89. Buckley F, Finckh A, Huizinga TWJ, et al. Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis J Man Care Spec Pharm 2015; 21: 409 — 423. DOI: 10.18553/jmcp.2015.21.5.409
90. Jansen JP, Buckley F1, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs — a systematic review and network meta-analysis. Healt Qual Life Ourcome 2014 Jul 3; 12: 102. doi: 10.1186/1477 — 7525 — 12102.
91. Singh JA, Hossain A, Tanjong Ghogomu E, Mudano AS, Tugwell P, Wells GA. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). Cochrane Database Syst Rev 2016 Nov 17; 11: CD012437.
92. Singh JA, Hossain A, Tanjong Ghogomu E, Mudano AS, Maxwell LJ, Buchbinder R et al. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017 Mar 10; 3: CD012591. doi: 10.1002/14651858.CD012591.
93. Salliot C, Finckh A, Katchamart W, et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 2011; 70: 266 — 71
94. Moots RJ, Naisbett-Groet B. The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. Rheumatology (Oxford) 2012; 51: 2252 — 61.
95. Schoels M, Aletaha D, Smolen JS, et al. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor alpha inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012; 71: 1303 — 8.
96. Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess 2011; 15: 1 — 278.
97. Emery P, Gottenberg JE, Rubbert-Roth A, Sarzi-Puttini P, Choquette D et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis 2015 Jun; 74(6): 979 — 84. doi: 10.1136/annrheumdis-2013-203993
98. Gottenberg J, Brocq O, Perdriger A, et al. In the multicenter randomized controlled rotation or change trial, a non-TNF targeted therapy has a higher efficacy than a second anti-TNF at 3, 6 and 12 months [abstract]. Arthritis Rheumatol. 2015; 67(Suppl 10): Abstract 3110.
99. Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs — a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014; 73: 529 — 535. doi10.1136/annrheumdis-2013-204575.
100. Woodrick RS, Ruderman EM. Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol 2011; 7, 639 — 652
101. Boyman O, Comte D, Spertini F. Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol 2014; 10: 612 — 627. Doi: 10.1038/nrrheuum.2014.123.
102. Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМАПРЕСС; 2013.
103. Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2017 Mar
104. Tarp S, Eric Furst D, Boers M, Luta G, Bliddal H, Tarp U, Heller Asmussen K, Brock B, Dossing A, , Thirstrup S, Christensen R. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. Rheumatology (Oxford). 2017 Mar 1; 56(3): 417425. doi: 10.1093/rheumatology/kew442.
105. Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015; 386(9990): 258 — 65.
106. Michaud TL, Rho YH, Shamliyan T, Kuntz KM, Choi HK. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. Am J Med. 2014 Dec; 127(12): 1208 — 32. doi: 10.1016/j.amjmed.2014.06.012.
107. Bredermeier M, de Oliveira FK, Rocha CM. Low-versus highdose rituximab for rheumatoid arthritis: a systemic review and meta-analysis. Arthritis Care Res 2014; 66: 228 — 235 doi: 10.1002/acr.22116
108. Hochberg M, Janssen K, Broglio K, et al. Comparison of abatacept and other biologic DMARDs for the treatment of rheumatoid arthritis: a systemic literature review and network meta-analysis. Ann Rheum Dis 2015; 72 (Suppl.4): 678.
109. Maneiro RJ, Salgado E, Carmona L, Gomez-Reino JJ. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. Semin Arthritis Rheum. 2013 Aug; 43(1): 9 — 17. doi: 10.1016/j.semarthrit.2012.11.007. Epub 2013
110. Alten R, , Mariette X, Galeazzi M, Lorenz HM, Cantagrel A, Chartier M, Poncet C, Rauch C, Le Bars M. Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic : 6-month results from a real-world, international, prospective study RMD Open. 2017 Feb 13; 3(1): e000345. doi: 10.1136/rmdopen-2016-000345
111. Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, , Pavelka K, Hetland ML, Turesson C, Mariette X, Finckh A. Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis. Arthritis Rheumatol. 2016 Jun; 68(6): 1346 — 52. doi: 10.1002/art.39595.
112. Sokolove J, Schiff M, Fleischmann R, Weinblatt ME, Connolly SE, Johnsen A, Zhu J, Maldonado MA, Patel S, Robinson WH. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis. 2016 Apr; 75(4): 709 — 14. doi: 10.1136/annrheumdis-2015207942
113. Schett G, Emery P, Tanaka Y, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis 201610: 1 — 10. Doi.10.1136/annrheumdis-2016-209201.
114. Verhoef LM, Tweehuysen L, Hulscher ME, Fautrel B, den Broeder AA. bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search. Rheumatol Ther 2017 Mar 2. doi: 10.1007/s40744-017-0055-5
115. Edwards CJ, Fautrel B, Schulze-Koops H, Huizinga TW, Kruger K. Dosing down with biologic therapies: a systematic review and clinicians» perspective. Rheumatology (Oxford) 2017 Feb 16. doi: 10.1093/rheumatology/kew464
116. Winthrop KL, Iseman M. Bedfellows: Mycobacteria and rheumatoid arthritis in the era of biologic therapy. Nat Rev Rheumatol 2013; 9: 524 — 531. doi: 10.1038/nrrheum.2013.82
117. Baillet A, Gossec L, Carmona L, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. Ann Rheum Dis 2016; 75: 965 — 73. doi: 10.1136/annrheumdis-2016-209233
118. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative. J Rheumatol 2015; 42: 1767 — 80.
119. Richards JS, Dowell SM, Quinones ME, Kerr GS. How to usebiologic agents in patients with rheumatoid arthritis who have comorbid disease. BMJ 2015; 17; 351: h3658. doi: 10.1136/bmj.h3658.
120. Westlake S. L., Colebatch A. N., Baird J., et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology. 2010; 49(2): 295 — 307. doi: 10.1093/rheumatology/kep366
121. Westlake S. L., Colebatch A. N., Baird J., et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology. 2011; 50(3): 518 — 531. doi: 10.1093/rheumatology/keq316
122. Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, , Ridker PM, Mozaffarian D. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011 Nov 1; 108(9): 1362 — 70. doi: 10.1016/j.amjcard.2011.06.054.
123. Roubille C, Richer V, Startino T, et al. The effect of tumor necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systemic review and meta-analysis. Ann Rheunm Dis 2015; 74: 480 — 489. Doi: 10.1136/annrheumdis-2014-206624.
124. Barnabe C., Martin B.-J., Ghali W. A. Systematic review and meta-analysis: anti-tumor necrosis factor therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care & Research. 2011; 63(4): 522 — 5029. doi: 10.1002/acr.20371
125. van Assen S., Agmon-Levin N., Elkayam O., et al: EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70: 414 — 422
126. Friedman MA, Winthrop KL. Vaccines and disease-modifying Antirheumatic Drugs: Practical Implications for the Rheumatologist. 2017; 43(1): 1 — 13. doi: 10.1016/j.rdc.2016.09.003. Epub 2016 Oct 22.
127. Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002; 61: 4 290 — 297 doi: 10.1136/ard.61.4.290
128. Villeneuve E, Nam JL, Bell MJ et al. A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis. Ann Rheum Dis 2013; 72: 13 — 22. doi: 10.1136/annrheumdis-2011-201063
129. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007; 66: 34 — 45.
130. Combe B, , Daien CI, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis 2016; doi: 10.1136/annrheumdis-2016-210602. doi: 10.1136/annrheumdis-2016-210602
131. Aletaha D, Neogri T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria. An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569 — 81
132. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31: 31524.
133. Амирджанова В.Н. Автореферат диссертации на соисканиеученой степени доктора медицинских наук «Ревматоидный артрит и качество жизни: методология исследований, валидация инструментов, оценка эффективности терапии». Москва 2008 г.
134. Van der Heijde D, van der Helm-van Mil AHM, Aletaha D, et al. EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. AnnRheumDis. 2013; 72: 479 — 81. doi: 10.1136/annrheumdis-2012-202779
135. Colebatch AN, Edwards CJ, Ostergaard M, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis. 2013; 72: 80414. doi: 10.1136/annrheumdis-2012-203158
136. Mangnus L, Schoones JW, van der Helm-van Mil AHM. What is the prevalence of MRI-detected inflammation and erosions in small joints in the general population? A collation and analysis of published data. RMD Open. 2015; 1: e000005. doi: 10.1136/rmdopen-2014-000005
137. Heimans L, van den Broek M, le Cessie S, et al. Association of high body mass index with decreased treatment response to combination therapy in recent-onset rheumatoid arthritis patients. Arthritis Care Res. 2013; 65: 1235 — 42. doi: 10.1002/acr.21978
138. Sandberg MEC, Bengtsson C, , et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis. 2014; 73: 202933. doi: 10.1136/annrheumdis-2013-205094
139. Wevers-de Boer K, Visser K, Heimans L, et al. Extended report: remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). Ann Rheum Dis. 2012; 71: 1472 — 7. doi: 10.1136/annrheumdis-2011-200736
140. Mirpourian M, Salesi M, Abdolahi H, et al. The association of body mass index with disease activity and clinical response to combination therapy in patients with rheumatoid arthritis. J Res Med Sci Off J Isfahan Univ Med Sci. 2014; 19: 509 — 14.
141. Saevarsdottir S, Rezaei H, Geborek P, et al. Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial. AnnRheumDis. 2015; 74: 1509 — 14. doi: 10.1136/annrheumdis-013-204601-150
142. Saevarsdottir S, Wedren S, Seddighzadeh M, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum. 2011; 63: 26 — 36. doi: 0.1002/art.27758
143. Rojas-Serrano J, Perez LL, Garcia CG, et al. Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study. Clin Rheumatol. 2011; 30: 1589 — 93. doi: 10.1007/s10067-011-1775-5
144. Wessels JAM, van der Kooij SM, le Cessie S, et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis.Arthritis Rheum. 2007; 56: 1765 — 75. doi: 10.1002/art.22640
145. Ekelman BA, Hooker L, Davis A, et al. Occupational therapy interventions for adults with rheumatoid arthritis: an appraisal of the evidence. Occup Ther Health Care. 2014; 28: 347 — 61. doi: 10.3109/07380577.2014.919687
146. Hurkmans E, van der Giesen FJ, Vliet Vlieland TP, et al. Dynamic exercise programs (aerobic capacity and/or muscle strength training) in patients with rheumatoid arthritis. Cochrane Database Syst Rev. 2009; (4): CD006853. doi: 10.1002/14651858.CD006853.pub2
147. Manning VL, Hurley MV, Scott DL, et al. Education, self-management, and upper extremity exercise training in people with rheumatoid arthritis: a randomized controlled trial. Arthritis Care Res. 2014; 66: 217 — 27. doi: 10.1002/acr.22102
148. Mathieux R, Marotte H, Battistini L, et al. Early occupational therapy programme increases hand grip strength at 3 months: results from a randomised, blind, controlled study in early rheumatoid arthritis. Ann Rheum Dis. 2009; 68: 400 — 3. doi: 10.1136/ard.2008.094532
149. Zangi HA, Ndosi M, Adams J, et al. EULAR recommendations for patient education for people with inflammatory arthritis. Ann Rheum Dis. 2015; 74: 954 — 62. doi: 10.1136/annrheumdis-2014-206807
Источник статьи: http://sudact.ru/law/klinicheskie-rekomendatsii-revmatoidnyi-artrit-utv-minzdravom-rossii/klinicheskie-rekomendatsii/spisok-literatury/literatura/